About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Advance Visual Communicaitons evaluating number of investments
LONDON (AFX) - Advance Visual Communications PLC, which has now completed
the process of disposing of all its interests in the subsidiaries formerly held,
said it is evaluating a number of investments.
The group today reported a loss before and after tax of 69,500 stg for the
year to June 30 2006.
It said cash balances at the period end were 25,431 stg, adding that it is
endeavouring to minimize the cash outflow.
The board said it looks forward to reporting further with a positive
proposal.



IN WHAT WAY CAN THEY OFFER ANYTHING POSSITIVE

;-)

ph you ok, see your geting a hard time over on the dark side, : )

Well I wanted a bit of company ;-)

Pipeline update from OSI pharma re ERX tomorrow, and MGI pharma pipeline update re ERX ZYC300 on wednesday

cant wait!!!

Bio-IT Briefs November 27, 2006 | The National Library of Medicine (NLM), a part of the National Institutes of Health (NIH), is awarding 18 five-year grants, totaling more than $75million, for research training in biomedical informatics, the discipline that seeks to apply computer and communications technology to the field of health. For more than 30 years, NLM has been the primary sponsor of biomedical informatics research training in the United States. At its current group of 18 informatics programs, NLM supports nearly 300 pre-doctoral and post-doctoral trainees each year. Trainees come to these programs with a range of educational and professional backgrounds; the group includes physicians, biologists, computer scientists, and engineers. Read the press release.

Artemis Pharmaceuticals GmbH has signed a research agreement with Merck & Co. Inc. to construct a large number of shRNA interference ("shRNAi ") - genetically engineered mouse models for the in vivo functional analysis of selected disease related genes. The agreement represents a significant initiative to undertake a large-scale approach to gene function analysis using shRNA knock down in genetically engineered mice as models for human biology. Under the terms of the agreement, Artemis will generate genetically engineered shRNAi "knock down" mouse models for Merck using Artemis' proprietary, optimized and fully integrated vector construction, ES cell transfection and inducible RNAi technology. Merck will provide selected shRNA sequences that correspond to mouse genes that may also play a central role in human diseases. Artemis will use its technologies to achieve constitutive as well as inducible functional down-regulation of the expression of the gene targets provided by Merck. Read the press release.

Kendle, a Cincinnati-based clinical research organization, has appointed Sylva Collins as vice president of global biometrics. Collins formerly ran electronic data management for Novartis, managing more than 400 EDC studies approximately 130,000 patients worldwide. She will oversee Kendles global Biometrics services, including clinical data management, biostatistics and scientific programming. Website: www.kendle.com.

Agilent Technologies has launched a new product demonstration center at its Santa Clara, Calif., corporate headquarters, showcasing its life sciences and chemical analysis capabilities. The Center of Excellence launch follows the recent opening of a similar center in Bangalore, India, and recent expansions of Agilent product demonstration centers in Paris, France; Manchester, U.K.; and Waldbronn, Germany. Planned for late 2007 is yet another center in Little Falls, Delaware. Read the press release

exciting day tomorrow

what makes you so confident PH

OSI Pharmaceuticals to Present at the Lazard Life Sciences Conference on Tuesday, November 28, 2006
MELVILLE, N.Y.--(BUSINESS WIRE)--Nov. 17, 2006--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that Michael G. Atieh, Executive Vice President and Chief Financial Officer of OSI Pharmaceuticals will present at the Lazard Life Sciences Conference in New York, NY on Tuesday, November 28, 2006 at 8:00am (EST). Mr. Atieh will provide an overview on the Company's product portfolio and business developments.

RNS Number:2988Y
EiRx Therapeutics PLC
05 May 2004

EiRx Therapeutics (EiRx)



Announces Triggering of First Success Milestone Payments with OSI
Pharmaceuticals for the License of EiRx's Apoptosis Drug Targets



EiRx Therapeutics plc ("EiRx"). (LSE:AIM: ERX), the healthcare company
specialising in the control of programmed life and death of cells (apoptosis) is
pleased to announce its first major milestone agreement since its flotation on
AIM earlier this year with a potential value of up to US $18.8 million.



Following a 12 month period of Evaluation and Option, OSI Pharmaceuticals
("OSIP"), has elected to licence and take forward four of EiRx's novel
apoptosis gene targets into drug discovery for oncology. OSI Pharmaceuticals
(headquartered in Melville, NY), is a leading biotechnology company focused on
the discovery, development, and commercialization of high-quality, next-
generation oncology products. A success fee for each target is payable by OSIP,
as part of a deal consisting of upfront access and consultancy fees, potential
success fees for each target elected by OSIP to license and potential milestone
payments based on successful commercialisation of a novel therapeutic with
respect to each such target.




The presentation will be webcast live and may be accessed by visiting OSI's website at www.osip.com. A replay of the webcast will also be available on the Company's website until December 13, 2006.

About OSI Pharmaceuticals

OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality and novel pharmaceutical products designed to extend life and/or improve the quality of life for patients with cancer and diabetes/obesity. The Company's oncology programs are focused on developing molecular targeted therapies designed to change the paradigm of cancer care. OSI's diabetes/obesity efforts are committed to the generation of novel, targeted therapies for the treatment of type 2 diabetes and obesity. OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in both non-small cell lung cancer and pancreatic cancer patients in certain settings. OSI markets Tarceva through partnerships with Genentech, Inc. in the United States and with Roche throughout the rest of the world. For additional information about OSI, please visit (http://www.osip.com).

Old news (again), PH

I noticed that you did leave the date in this time, but these old posts can sometimes be misleading if not read in conjunction with historical events.

Perhaps you should have included the following part from the 2005 Finals (August of that year):

OSI

Another key milestone this year was the licensing agreement with the leading
biotechnology company, OSI Pharmaceuticals, Inc., which is headquartered in
Melville, New York, U.S.A. ('OSI'). Following a 12-month evaluation and option
period, OSI elected to take four of EiRx's novel apoptosis targets into drug
discovery for oncology. The potential value of this deal is worth up to US
$18.8 million over a period of, possibly, ten years. As well as the financial
considerations, EiRx views this transaction as an endorsement of its ALIBITM
technology's ability to identify novel oncology targets and the potential of
further patented targets. We look forward to OSI advancing these targets
successfully through drug discovery and are optimistic that this will lead to
milestone payments to EiRx.

Two points to note:

1. license fee of $18.8m over a period of possibly 10 years.
2. use of the words potential and optimistic.

Summary - there is no guarantee of any license fees and just because OSI are presenting at some conference tomorrow means diddly squat to EiRX. They are very unlikely to be announcing at a conference that they are about to hand a large wad of cash over to EiRX. For all we know, they may be presenting a paper on a subject that has absolutely no connection with EiRX, afterall, they do have other research areas of their own.

Lets all try to be realistic.

Webcast
OSI Pharmaceuticals, Inc. at Lazard Third Annual Life Sciences Conference (Live)
11/28/06 at 8:00 a.m. ET

OSI Pharmaceuticals to Present at the Lazard Life Sciences Conference on Tuesday, November 28, 2006
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that Michael G. Atieh, Executive Vice President and Chief Financial Officer of OSI Pharmaceuticals will present at the Lazard Life Sciences Conference in New York, NY on Tuesday, November 28, 2006 at 8:00am (EST). Mr. Atieh will provide an overview on the Companys product portfolio and business developments.

The presentation will be webcast live and may be accessed by visiting OSIs website at www.osip.com. A replay of the webcast will also be available on the Companys website until December 13, 2006.

About OSI Pharmaceuticals OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality and novel pharmaceutical products designed to extend life and/or improve the quality of life for patients with cancer and diabetes/obesity. The Companys oncology programs are focused on developing molecular targeted therapies designed to change the paradigm of cancer care. OSIs diabetes/obesity efforts are committed to the generation of novel, targeted therapies for the treatment of type 2 diabetes and obesity. OSI's flagship product, Tarceva (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in both non-small cell lung cancer and pancreatic cancer patients in certain settings. OSI markets Tarceva through partnerships with Genentech, Inc. in the United States and with Roche throughout the rest of the world. For additional information about OSI, please visit .

This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, the completion of clinical trials, the FDA and other foreign review processes and other governmental regulation, OSI's and its collaborators' abilities to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, the ability to effectively market products, and other factors described in OSI Pharmaceuticals' filings with the Securities and Exchange Commission.

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that Michael G. Atieh, Executive Vice President and Chief Financial Officer of OSI Pharmaceuticals will present at the Lazard Life Sciences Conference in New York, NY on Tuesday, November 28, 2006 at 8:00am (EST). Mr. Atieh will provide an overview on the Company's product portfolio and business developments.

The presentation will be webcast live and may be accessed by visiting OSI's website at www.osip.com. A replay of the webcast will also be available on the Company's website until December 13, 2006.

About OSI Pharmaceuticals

OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality and novel pharmaceutical products designed to extend life and/or improve the quality of life for patients with cancer and diabetes/obesity. The Company's oncology programs are focused on developing molecular targeted therapies designed to change the paradigm of cancer care.

OSI's diabetes/obesity efforts are committed to the generation of novel, targeted therapies for the treatment of type 2 diabetes and obesity. OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in both non-small cell lung cancer and pancreatic cancer patients in certain settings. OSI markets Tarceva through partnerships with Genentech, Inc. in the United States and with Roche throughout the rest of the world. For additional information about OSI, please visit (http://www.osip.com).

8am EST is what in Britain please?

Hi Laurie
I think it's about 1pm but i maybe wrong

keith

someone just bought 20mil

Zyzygy Directorate Change
RNS Number:8246M
Zyzygy PLC
28 November 2006

Zyzygy plc ("Zyzygy" or the "Company")

Resignation of Director

28 November 2006

The Company announces that John Pool has stood down from the board with
immediate effect. The directors of Zyzygy would like to take this opportunity to
thank Mr. Pool for his contribution to the Company.



Contact:

Zyzygy Directorate Change
RNS Number:8246M
Zyzygy PLC
28 November 2006

Zyzygy plc ("Zyzygy" or the "Company")

Resignation of Director

28 November 2006

The Company announces that John Pool has stood down from the board with
immediate effect. The directors of Zyzygy would like to take this opportunity to
thank Mr. Pool for his contribution to the Company.



Contact:

something to do with the big plan

Zyzygy Directorate Change
RNS Number:8246M
Zyzygy PLC
28 November 2006

Zyzygy plc ("Zyzygy" or the "Company")

Resignation of Director

28 November 2006

The Company announces that John Pool has stood down from the board with
immediate effect. The directors of Zyzygy would like to take this opportunity to
thank Mr. Pool for his contribution to the Company.



Contact:
potatohead - 28 Nov 2006 12:07 - 622 of 622
something

Why would this be positive news-I thought he was the main man???